S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
Indian tycoon Adani hit by more losses, calls for probe
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
Indian tycoon Adani hit by more losses, calls for probe
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
Indian tycoon Adani hit by more losses, calls for probe
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
Indian tycoon Adani hit by more losses, calls for probe
NASDAQ:ALNY

Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

$233.37
+3.62 (+1.58%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$227.63
$234.02
50-Day Range
$204.79
$241.31
52-Week Range
$117.58
$242.97
Volume
1.20 million shs
Average Volume
790,216 shs
Market Capitalization
$28.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$239.84

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.68 Rating Score
Upside/​Downside
4.4% Upside
$243.72 Price Target
Short Interest
Bearish
4.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.71mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$378,567 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.62) to ($6.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

976th out of 1,029 stocks

Pharmaceutical Preparations Industry

473rd out of 501 stocks

ALNY stock logo

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Needham Keeps Their Buy Rating on Cidara Therapeutics (CDTX)
3 Growth Stocks That Could Rocket Higher in 2023
SVB Securities Reaffirms Their Hold Rating on Wave Life Sciences (WVE)
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings
10/27/2021
Today
2/04/2023
Next Earnings (Confirmed)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
1,665
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$243.72
High Stock Price Forecast
$415.00
Low Stock Price Forecast
$143.00
Forecasted Upside/Downside
+2.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.68
Research Coverage
19 Analysts

Profitability

Net Income
$-852,820,000.00
Net Margins
-123.02%
Pretax Margin
-122.83%

Debt

Sales & Book Value

Annual Sales
$844.29 million
Book Value
$4.92 per share

Miscellaneous

Free Float
121,306,000
Market Cap
$28.71 billion
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Yvonne L. GreenstreetYvonne L. Greenstreet
    Chief Executive Officer & Director
  • Akshay K. VaishnawAkshay K. Vaishnaw
    President
  • Jeffrey V. Poulton
    Chief Financial Officer & Executive Vice President
  • Pushkal P. Garg
    Chief Medical Officer & EVP-Medical Affairs
  • James P. Bilotta
    Chief Information Officer & SVP













ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price forecast for 2023?

19 brokerages have issued 1 year price objectives for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $143.00 to $415.00. On average, they predict the company's share price to reach $243.72 in the next year. This suggests a possible upside of 4.9% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2023?

Alnylam Pharmaceuticals' stock was trading at $237.65 at the start of the year. Since then, ALNY stock has decreased by 2.2% and is now trading at $232.35.
View the best growth stocks for 2023 here
.

Are investors shorting Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totaling 5,680,000 shares, an increase of 11.2% from the December 31st total of 5,110,000 shares. Based on an average daily trading volume, of 783,400 shares, the days-to-cover ratio is presently 7.3 days.
View Alnylam Pharmaceuticals' Short Interest
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings data on Wednesday, October, 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.51) by $0.21. The biopharmaceutical company earned $187.63 million during the quarter, compared to analyst estimates of $218.69 million. Alnylam Pharmaceuticals had a negative net margin of 123.02% and a negative trailing twelve-month return on equity of 430.74%. The company's revenue was up 49.1% compared to the same quarter last year. During the same period last year, the business posted ($2.18) EPS.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (7.65%), Sumitomo Mitsui Trust Holdings Inc. (0.27%), New York State Common Retirement Fund (0.13%), Tobam (0.09%), DekaBank Deutsche Girozentrale (0.07%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $232.35.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $28.59 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($9.77) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

The company employs 1,665 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 2/4/2023 by MarketBeat.com Staff